Drug Trial Radar · NCT03452943
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Feb 5, 2018
Primary completion
Nov 12, 2019
Study completion Nov 12, 2019
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Nuvelution TS Pharma, Inc.
- First posted
- Mar 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.
Conditions
- Tourette Syndrome
Interventions
TEV-50717Drug
6, 9, 12, 15, and 18 mg oral tablets
PlaceboDrug
Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the TTS of the YGTSS at Week 12Time frame: Baseline, Week 12
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
Teva Investigational Site 046-0104
Dothan, Alabama
Teva Investigational Site 046-0117
Sun City, Arizona
Teva Investigational Site 046-0107
Rogers, Arkansas
Teva Investigational Site 046-0126
Anaheim, California
Teva Investigational Site 046-0101
Sacramento, California
Teva Investigational Site 046-0111
San Diego, California
Teva Investigational Site 046-0130
Santa Ana, California
Teva Investigational Site 046-0132
Miami, Florida
Teva Investigational Site 046-0115
Orlando, Florida
Teva Investigational Site 046-0114
St. Petersburg, Florida
Teva Investigational Site 046-0116
Atlanta, Georgia
Teva Investigational Site 046-0133
Naperville, Illinois
Teva Investigational Site 046-0128
Boston, Massachusetts
Teva Investigational Site 046-0110
Saint Charles, Missouri
Teva Investigational Site 046-0134
Lincoln, Nebraska
Teva Investigational Site 046-0109
Voorhees Township, New Jersey
Teva Investigational Site 046-0124
New York, New York
Teva Investigational Site 046-0102
Rochester, New York
Teva Investigational Site 046-0112
Rochester, New York
Teva Investigational Site 046-0125
Raleigh, North Carolina
Teva Investigational Site 046-0106
Oklahoma City, Oklahoma
Teva Investigational Site 046-0113
Dallas, Texas
Teva Investigational Site 046-0108
Houston, Texas
Teva Investigational Site 046-0103
Houston, Texas
Teva Investigational Site 046-0120
San Antonio, Texas
Teva Investigational Site 046-0105
Orem, Utah
Teva Investigational Site 046-0118
Petersburg, Virginia
Teva Investigational Site 046-0201
Ajax, Ontario, Canada
Teva Investigational Site 046-0202
Ottawa, Ontario, Canada
Teva Investigational Site 046-0302
Herlev, Denmark
Teva Investigational Site 046-0301
Odense, Denmark
Teva Investigational Site 046-0702
Stavropol, Russia
Teva Investigational Site 046-0704
Tomsk, Russia
Teva Investigational Site 046-0703
Voronezh, Russia
Teva Investigational Site 046-1702
Belgrade, Serbia
Teva Investigational Site 046-1703
Belgrade, Serbia
Teva Investigational Site 046-1701
Novi Sad, Serbia
Teva Investigational Site 046-0604
Barcelona, Spain
Teva Investigational Site 046-0605
Madrid, Spain
Teva Investigational Site 046-0602
Madrid, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.